Previous close | 25.58 |
Open | 25.45 |
Bid | 25.51 x 100 |
Ask | 25.66 x 100 |
Day's range | 25.45 - 25.75 |
52-week range | 16.54 - 28.13 |
Volume | |
Avg. volume | 81,009 |
Market cap | 379.452M |
Beta (5Y monthly) | 0.75 |
PE ratio (TTM) | N/A |
EPS (TTM) | -5.64 |
Earnings date | 08 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 30.33 |
Many investors define successful investing as beating the market average over the long term. But the risk of stock...
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesday, May 8, 2024 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-888-886-7786 (
Here is how DexCom (DXCM) and Anika Therapeutics (ANIK) have performed compared to their sector so far this year.